Login to Your Account

Four years after its launch, Xtuit Pharmaceuticals Inc. came out of virtual mode with a $22 million series A that should suffice to advance its lead candidates in oncology and liver fibrosis through human proof-of-concept studies.
SHANGHAI – New out of the gate, Suzhou Neupharma Co. Ltd., has put its first candidate, RX-108, into clinical trials. Like many companies in China with global ambitions, Neupharma is collecting its first-in-human data in Australia while it waits for its trials to get a green light in China.
LONDON – "Drugging the undruggable" is the bold claim newco Phoremost Ltd. is making for its technology. The Cambridge University spinout said it can systematically identify and access intracellular targets that are undruggable using classic approaches.
More Newco News Headlines

Cast Your Vote

Should there be restrictions on the use of gene-editing technology?: